153 results
Page 4 of 8
8-K
EX-99.1
yeoi88k
5 Nov 20
Results of Operations and Financial Condition
8:40am
8-K
EX-99.1
t3n aamxyzmd3ez4u3
28 Sep 20
Heron Therapeutics Receives European Commission Authorization for ZYNRELEFTM (HTX-011) for the Treatment of Postoperative Pain
8:41am
8-K
EX-99.1
nn6dhx5gcjpjq 406
16 Sep 20
Regulation FD Disclosure
8:40am
8-K
EX-99.1
y9fa7q
8 Sep 20
Heron Therapeutics Announces Successful Outcome of FDA Type A Meeting to Discuss HTX-011 for the Management of Postoperative Pain
8:41am
8-K
EX-99.1
palj11ju8h4hjcxl
5 Aug 20
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.1
ryuzfhugdvv15j uc7
24 Jul 20
Heron Therapeutics Receives Positive CHMP Opinion for ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain
8:40am
8-K
EX-99.1
xvxyb0lr2bzue
16 Jul 20
Heron Therapeutics Announces Initiation of
8:40am
8-K
EX-99.1
jjfrmuoqysjo5vs 6ig
29 Jun 20
Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain
4:06pm
8-K
EX-99.1
6gft7ry43h
4 Jun 20
Regulation FD Disclosure
9:14am
8-K
EX-99.1
cc7jgokf73rm6 ox5d7b
18 May 20
Heron Therapeutics Announces Initiation of Phase 1b/2 Clinical Study of HTX-034 for the Treatment of Postoperative Pain
9:11am
8-K
EX-99.1
plz06hm72f6
6 May 20
Results of Operations and Financial Condition
9:10am
8-K
EX-99.1
wvgz9y
2 Mar 20
Results of Operations and Financial Condition
7:44am
8-K
EX-99.1
5cx87
19 Feb 20
Heron Therapeutics Announces FDA Extension of Review Period for NDA for HTX-011 for the Management of Postoperative Pain
4:37pm
8-K
EX-99.2
wpz4bd6jg
13 Jan 20
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
8:41am
8-K
EX-99.1
6cu 2cgvqt54
13 Jan 20
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
8:41am
8-K
EX-99.1
b1zqfsp
16 Dec 19
Regulation FD Disclosure
4:15pm